Medida por consenso del estado de la innovación en medicina física y rehabilitación / Consensus measurement of innovation in physical medicine and rehabilitation

Objetivo: Valorar el estado actual y el potencial de innovación del colectivo de profesionales de la especialidad médica de medicina física y rehabilitación (MFRHB) en España. Método: Se aplicaron 3técnicas consecutivas mediante herramientas digitales para el consenso entre profesionales: primero de forma síncrona a un colectivo de 17 profesionales, después se extendió a un colectivo de 169 que participaron de forma asíncrona y la tercera técnica se realizó de forma síncrona con 25 médicos especialistas en MFRHB. Resultados: Se dispuso del análisis consensuado por los propios profesionales sobre el potencial de innovación del colectivo realizado en octubre y noviembre del 2020: situación de partida, puntos fuertes y puntos débiles, así como sus prioridades en innovación. Conclusiones: Los médicos especialistas en MFRHB consideran que la innovación podría mejorar el coste efectividad de los servicios y podría aumentar su eficiencia clínica; también consideran que para innovar necesitan una relación estrecha con la industria.(AU)

Objective: To measure by consensus the level of innovation and its potential within the physical medicine and rehabilitation (PM&R) medical specialists. method: Three consecutive techniques are applied using digital tools for consensus among professionals, first synchronously to a group of 17 professionals; posteriorly extended to a group of 169 professionals who participate asynchronously and the third technique is done synchronously with 25 physiatrists. Results: The analysis of the consensus done by the PM&R physicians on the innovation potential of the group during October and November 2020 shows: starting situation, strengths and weaknesses, as well as their innovation priorities. Conclusions: PM&R physicians believe that innovation could improve the cost-effectiveness of their departments, and could increase their clinical efficiency, also that to innovate they need a close relationship with the industry.(AU)

[Consensus measurement of innovation in physical medicine and rehabilitation]. / Medida por consenso del estado de la innovación en medicina física y rehabilitación.

OBJECTIVE: To measure by consensus the level of innovation and its potential within the physical medicine and rehabilitation (PM&R) medical specialists. METHOD: Three consecutive techniques are applied using digital tools for consensus among professionals, first synchronously to a group of 17 professionals; posteriorly extended to a group of 169 professionals who participate asynchronously and the third technique is done synchronously with 25 physiatrists. RESULTS: The analysis of the consensus done by the PM&R physicians on the innovation potential of the group during October and November 2020 shows: starting situation, strengths and weaknesses, as well as their innovation priorities. CONCLUSIONS: PM&R physicians believe that innovation could improve the cost-effectiveness of their departments, and could increase their clinical efficiency, also that to innovate they need a close relationship with the industry.

La rehabilitación en los tiempos del COVID-19 / Rehabilitation in the time of COVID-19

No disponible

Successful heart transplantation in patients with inherited myopathies associated with end-stage cardiomyopathy.

UNLABELLED: Inherited myopathies in patients with secondary end-stage cardiomyopathies have always been considered a relative contraindication for cardiac transplantation. High operative risk related to muscle impairment and potential graft involvement secondary to the underlying myopathy have been the two main reasons implicated in the poor prognosis. OBJECTIVE: The aim of this study was to evaluate the outcome in patients who underwent cardiac transplantation in our hospital due to end-stage cardiomyopathy secondary to inherited myopathies. METHODS: Among 311 patients who underwent heart transplantation in our hospital, five (2%) had end-stage cardiomyopathies related to inherited myopathies. Four patients had muscular dystrophy (three Becker's muscular dystrophy and one hips-dystrophy) and the fifth desminopathy. In one patient cardiomyopathy was the initial manifestation of the disease. Mean age at the time of transplantation was 38.6 years (range from 24 to 55). The mean follow-up after transplantation was 57.4 months (range from 13 to 128). The intraoperative and postoperative course of these individuals did not show higher complication rates than other patients. All recipients experienced successful rehabilitation; no evidence of graft dysfunction has been detected during follow-up. All of them are alive with a good performance status. CONCLUSIONS: In our experience, patients who underwent heart transplantation due to end-stage cardiomyopathy secondary to inherited myopathy with only a mild degree of muscle impairment did not display higher postoperative nor long-term complications compared to other recipients.

[Clinical factors associated with bone mass loss previous cardiac transplantation]. / Factores clínicos asociados a la pérdida de masa ósea previa al trasplante cardíaco.

BACKGROUND: A high prevalence of osteoporosis has been described in patients before and after cardiac transplantation. But clinical factors involved in previous bone loss in this condition are not well known. The purpose has been to study bone mineral density (BMD) in patients subject to cardiac transplantation, analyzing clinical and biochemical factors related to bone mass in these patients. PATIENTS AND METHODS: We have studied lumbar and hip BMD in 51 patients candidates to cardiac transplantation, evaluating the functional grade of the cardiopathy, time of evolution of the disease, and antropometric and biochemical markers of bone turnover. BMD was measured using a dual X ray densitometer. RESULTS: A significant decrease in bone mass at lumbar and hip sites was found in patients with regard to normal population. A high prevalence of osteoporosis was found (27.4%). Time of evolution of the disease prior to transplantation was found to be the most important predictive variable in bone loss at trabecular bone (lumbar spine). No modifications were found in blood routine parameters, mineral studies and in serum intact PTH. Resorption bone markers were increased and formation markers were normal, suggesting a elevated turnover osteoporosis. Patients with osteoporosis had less BMI that patients without, indicating a protective effect of body mass. Patients with osteoporosis also had a greater time of evolution of the disease. CONCLUSIONS: There is a decreased bone mass in lumbar spine and hip and a higher prevalence of osteoporosis in patients with cardiac failure before cardiac transplantation. Time of waiting for cardiac transplantation has been an important factor found in the development of metabolic bone disease in these patients.

Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation.

Cardiac transplantation is associated with severe bone loss caused by glucocorticoids, immunosuppressive treatment, and other factors. Treatment protocols for the prevention of bone loss is being studied. Forty patients who underwent cardiac transplantation were randomly given calcitonin (n = 13; 100 UI/d, nasal route), etidronate (n = 14; cyclical treatment 400 mg p.o./d/2 weeks/3 months), or calcidiol (n = 13; 32,000 IU/weekly) therapy for at least 18 months. Serum parameters (Ca, P, alkaline phosphatase, osteocalcin, intact PTH), urinary calcium, and vertebral mineral density (VMD; L2-L4, DXA Hologic QDR 1000) were measured immediately before treatment and after 6, 12, and 18 months of therapy after cardiac transplantation. Patients with cardiac transplantation had a VMD significantly lower than age and sex-matched Spanish controls. Prevalence of osteoporosis (Z-score below -2 SD) was 30%. Osteocalcin levels increased at 6, 12, and 18 months of treatment in the three groups. After 18 months of treatment, VMD increased significantly in the calcidiol 4.9%, vs. -1.19% and -0.19% in the calcitonin and etidronate groups, respectively. A lower incidence of fracture was found in patients treated with calcidiol during the study. In summary, we have found in this open randomized study that calcidiol was the most effective drug in the prevention and treatment of bone loss in patients after cardiac transplantation.